The present invention provides: a freeze-dried composition which comprises (a) a monovalent metal alginate and (b) a salt selected from a monovalent metal salt and an ammonium salt; and a method of producing a freeze-dried monovalent metal alginate composition which comprises the steps of freezing an aqueous solution formed by dissolving at least the component (a) and the component (b), performing first drying, and then performing second drying as desired to reduce a water content to 3% by mass or less. This is a freeze-dried monovalent metal alginate composition with suppressed viscosity decrease with the lapse of time.

Methods for neutralizing stomach acid in a subject including alginate-based nutritional products (“AP”). AP includes alginate as a reflux-neutralizing, raft-forming, stabilizing agent, including polylysine, dextrose and grapefruit seed extract preservatives. The methods are intended to provide relief or prophylaxis of acid reflux and other forms of indigestion in mammals. In some embodiments, dextrose and polylysine are combined to form a preservative for the alginate-based nutritional supplement. In other embodiments, a method for producing a reflux preventing raft is provided.

Methods for neutralizing stomach acid in a subject including alginate-based nutritional products (“AP”). AP includes alginate as a reflux-neutralizing, raft-forming, stabilizing agent, including polylysine, dextrose and grapefruit seed extract preservatives. The methods are intended to provide relief or prophylaxis of acid reflux and other forms of indigestion in mammals. In some embodiments, dextrose and polylysine are combined to form a preservative for the alginate-based nutritional supplement. In other embodiments, a method for producing a reflux preventing raft is provided.

A composition in powder form comprising alginic acid or sodium alginate, -pectin and chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder, the process for preparing the powder and its use in the treatment of cutaneous wounds and in the sector of food preservation are described.

A composition in powder form comprising alginic acid or sodium alginate, -pectin and chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder, the process for preparing the powder and its use in the treatment of cutaneous wounds and in the sector of food preservation are described.

An aspect is to provide a prebiotic for growing a butyrate-producing bacterium. A prebiotic composition for a butyrate-producing bacterium includes alginic acid and/or a salt thereof having an average molecular weight of 10000 or less.

An aspect is to provide a prebiotic for growing a butyrate-producing bacterium. A prebiotic composition for a butyrate-producing bacterium includes alginic acid and/or a salt thereof having an average molecular weight of 10000 or less.

The invention relates to a pharmaceutical composition containing alginate oligosaccharide diacid with formula (IV) or a pharmaceutically acceptable salt thereof, which can be used for preparing medicaments for treating Alzheimer's disease, Parkinson's disease, inflammation, pain, diabetes or vascular dementia.

##STR00001##

The invention relates to a pharmaceutical composition containing alginate oligosaccharide diacid with formula (IV) or a pharmaceutically acceptable salt thereof, which can be used for preparing medicaments for treating Alzheimer's disease, Parkinson's disease, inflammation, pain, diabetes or vascular dementia.

##STR00001##

A use that relates to mannuronic acid oligosaccharides or a composition comprising same in the treatment of Th1-dominance related diseases. The Th1-dominance related diseases may be selected from Multiple Sclerosis, Crohn's disease, Type I Diabetes, Rheumatoid Arthritis, Hashimoto's thyroiditis, vitiligo, Sjögren's Syndrome, Polycystic ovary syndrome, Celiac Disease and Grave's disease, preferably from Multiple Sclerosis, Crohn's disease and Rheumatoid Arthritis.